Survodutide vs Retatrutide: Next-Generation Dual and Triple Agonists Compared

Written by NorthPeptide Research Team  |  April 16, 2026

For laboratory and research use only. Not for human consumption.

The metabolic peptide research landscape has never moved faster. In the span of five years, scientists went from a single approved GLP-1 agonist (semaglutide) to a pair of approved dual agonists (tirzepatide), and now two of the most-watched pipeline compounds — survodutide and retatrutide — are racing through Phase 3 trials. Both activate the glucagon receptor. Both have produced striking liver fat data. And both are likely to reach regulatory submission in the 2026–2027 window.

So what actually separates them? The answer is more nuanced than “more receptors equals better.” This article examines the receptor profiles, clinical trial data, liver outcomes, side effect patterns, and development timelines of each compound for researchers tracking this space.

The Receptor Profiles: A Fundamentally Different Hypothesis

The first distinction is structural. Survodutide is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim (in partnership with Zealand Pharma) and identified by the research designation BI 456906. It engages two receptors. Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist developed by Eli Lilly, identified as LY3437943. It engages three.

The key difference is the second receptor. Survodutide replaces the GIP component — which tirzepatide uses — with nothing: it goes straight from GLP-1 to glucagon. Retatrutide keeps GIP and adds glucagon on top. This is not just an additive step. GIP and glucagon have distinct physiological roles:

• GIP receptor — Potentiates postprandial insulin secretion, influences lipid metabolism in adipose tissue, and may support beta-cell survival. In retatrutide’s potency profile, GIP is actually the highest-potency target (EC50: 0.0643 nM), with GLP-1 intermediate (EC50: 0.775 nM) and glucagon lowest (EC50: 5.79 nM).
• Glucagon receptor — Drives energy expenditure and thermogenesis in brown adipose tissue, stimulates hepatic fatty acid oxidation, and reduces de novo lipogenesis in the liver. This is the receptor both compounds share — and it is the mechanistic foundation of their liver fat data.

Survodutide’s hypothesis: GLP-1 + glucagon is sufficient to produce strong metabolic outcomes, with the GLP-1 component offsetting glucagon’s glucose-raising tendency. Retatrutide’s hypothesis: all three receptors together are additive or synergistic, with GIP providing incremental benefit over the dual combination.

Feature	Survodutide (BI 456906)	Retatrutide (LY3437943)
Developer	Boehringer Ingelheim / Zealand Pharma	Eli Lilly
Receptor Targets	GLP-1 + Glucagon (dual)	GLP-1 + GIP + Glucagon (triple)
Includes GIP Agonism?	No	Yes (highest-potency target)
Administration	Once-weekly subcutaneous	Once-weekly subcutaneous
Phase 3 Program Name	SYNCHRONIZE	TRIUMPH
Body Weight Reduction (Phase 2 peak)	~18–19% at 46 weeks	~24–29% at 48 weeks
MASH/MASLD Indication?	Yes — active Phase 3 for MASH	Yes — Phase 2a/3 for MASLD
Regulatory Status (2026)	Phase 3 — no approval	Phase 3 — no approval

Clinical Trial Programs: SYNCHRONIZE vs TRIUMPH

Survodutide: The SYNCHRONIZE Program

Boehringer Ingelheim’s Phase 3 program for survodutide is called SYNCHRONIZE. It follows Phase 2 results that were presented at major metabolic research conferences and published in peer-reviewed literature.

In the pivotal Phase 2 obesity trial — a randomized, double-blind, placebo-controlled study with a 46-week treatment period — survodutide produced the following outcomes at its highest doses:

• 18–19% mean body weight reduction at 46 weeks, compared to placebo. This positioned survodutide competitively against other agents in the class.
• Dose-dependent response — A clear titration curve was observed, with higher cohorts showing progressively greater weight reduction.
• No plateau signal — Weight loss continued through the end of the observation period at higher doses, suggesting ongoing receptor-mediated activity.

The Phase 2b MASH trial was, in some respects, the more striking dataset. In biopsy-confirmed MASH subjects, survodutide demonstrated significant reductions in hepatic fat content, a meaningful rate of MASH resolution (defined histologically as absence of steatohepatitis without worsening fibrosis), and early signals of fibrosis improvement. These outcomes led Boehringer Ingelheim to advance survodutide into Phase 3 MASH trials — a relatively rare move that positions it alongside resmetirom (the only FDA-approved MASH treatment as of 2026) in terms of clinical development priority (PMID 37565190).

SYNCHRONIZE Phase 3 trials are ongoing as of April 2026, with readouts expected in 2026–2027.

Retatrutide: The TRIUMPH Program

Eli Lilly’s TRIUMPH (Triple Receptor Agonist Investigation of Metabolic Pathways in Health) Phase 3 program has already produced one public readout. TRIUMPH-4, which investigated retatrutide in adults with obesity and knee osteoarthritis, reported results in December 2025:

• 26.4–28.7% body weight reduction at the highest dose studied — a figure that extended the Phase 2 findings (24.2% at 48 weeks, from the landmark NEJM publication) in a larger patient population (Jastreboff et al., NEJM 2023).
• Knee pain reduction — The trial met its co-primary musculoskeletal endpoint, the first demonstration of a peptide in this class producing meaningful joint pain improvement.
• Consistent adverse event profile — Safety findings were in line with Phase 2 data.

Additional TRIUMPH trials remain ongoing: TRIUMPH-1 (obesity without diabetes), TRIUMPH-2 (obesity with type 2 diabetes), TRIUMPH-3 (maintenance), and dedicated MASLD, sleep apnea, and cardiovascular outcomes studies. Regulatory submission is anticipated in late 2026 to mid-2027 (PMC12190491).

Liver Fat and MASLD/MASH: The Glucagon Advantage

Both compounds activate the glucagon receptor, and both have produced notable liver fat data. This is not coincidental — it reflects the mechanistic contribution of glucagon receptor agonism specifically. Glucagon receptor activation in hepatocytes directly stimulates fatty acid beta-oxidation and suppresses de novo lipogenesis, a combination that reduces liver fat through a hepatic-targeted mechanism that GLP-1 and GIP receptor agonism do not directly provide.

Survodutide MASH Data

In the Phase 2b MASH trial, survodutide demonstrated:

• Significant reduction in hepatic fat content as measured by imaging (MRI-PDFF)
• Histological resolution of MASH in a significant proportion of subjects
• Early fibrosis improvement signals, though longer follow-up is required for definitive fibrosis endpoints

The magnitude of liver fat reduction and MASH resolution rate from survodutide’s Phase 2b trial has not been precisely replicated in publicly available survodutide data, but the clinical decision to pursue a Phase 3 MASH program suggests confidence in the signal (PMID 37565190).

Retatrutide MASLD Data

Retatrutide’s liver fat data has been among the most discussed findings in metabolic peptide research in recent years. A Phase 2a trial published in Nature Medicine reported:

• 82–86% relative reduction in liver fat content (MRI-PDFF) at 48 weeks across the higher dose cohorts
• Resolution of hepatic steatosis in over 85% of subjects — achieving liver fat below the 5% diagnostic threshold

These findings were presented at the AASLD Liver Meeting and have positioned retatrutide as one of the most potent investigational agents for hepatic steatosis in the current research pipeline (Sanyal et al., Nature Medicine 2024).

Whether the magnitude of retatrutide’s liver fat data relative to survodutide reflects the additional GIP component, differences in dose, or trial design differences is not yet established. Head-to-head data does not exist.

Side Effects and Safety Profiles

Both compounds share the GLP-1 receptor as a common target, meaning both carry the class-effect GI side effect profile associated with GLP-1 agonism. The patterns are similar:

Shared GLP-1 Class Effects

• Nausea — The most frequently reported adverse event for both compounds in Phase 2 data. Dose-dependent and most pronounced during the escalation period.
• Vomiting and diarrhea — Less common than nausea, generally mild-to-moderate, tending to attenuate with continued exposure.
• Constipation — Consistent with GLP-1-mediated gastric emptying delay.
• Decreased appetite — An expected pharmacodynamic effect of GLP-1 receptor activation, present in both compounds.

Glucagon-Specific Considerations

The theoretical concern with glucagon receptor agonism — that co-activation of a glucose-raising receptor would cause hyperglycemia — has not materialized as a clinically significant finding in published Phase 2 data for either compound. The GLP-1 component (and, for retatrutide, GIP) appears to provide sufficient glycemic counter-regulation to offset glucagon’s glycogenolytic activity. However, glycemic monitoring remains an active area of safety surveillance in both Phase 3 programs.

Potential Differentiators

Retatrutide’s additional GIP receptor engagement raises the question of whether GIP agonism adds any distinct tolerability considerations beyond the shared GLP-1/glucagon profile. Published Phase 2 data did not identify major safety signals unique to retatrutide beyond the GI effects, but the full Phase 3 dataset will provide a more comprehensive tolerability picture. Survodutide’s simpler dual mechanism makes its safety profile more straightforward to interpret in the context of mechanism — the GI effects are attributed to GLP-1, and glucagon’s glycemic potential is the primary monitoring target.

Discontinuation rates due to adverse events in Phase 2 trials were reported as low for both compounds, consistent with the use of gradual dose-escalation protocols across both programs (PMC12304053).

Development Timeline and Regulatory Outlook

As of April 2026, both compounds are in Phase 3 without regulatory approval from the FDA or any other authority. The expected sequence:

• Retatrutide — TRIUMPH-4 results published December 2025. Remaining TRIUMPH trials reporting through 2026–2027. Regulatory submission anticipated late 2026 to mid-2027.
• Survodutide — SYNCHRONIZE Phase 3 trials ongoing, results expected through 2026–2027. Parallel Phase 3 MASH program creates a dual-indication submission pathway that could accelerate overall regulatory visibility.

Boehringer Ingelheim’s pursuit of a MASH indication alongside obesity is a distinguishing strategic choice. MASH is a disease with very few approved treatments (only resmetirom as of 2026), creating a regulatory pathway with potentially less competition. If survodutide’s Phase 3 MASH data replicates Phase 2 findings, it could achieve a first approval in MASH before its obesity indication is complete.

What This Means for Research

Both survodutide and retatrutide are available for laboratory investigation as research peptides. Researchers choosing between them should consider what receptor hypothesis they are testing:

• Testing GLP-1 + glucagon dual agonism specifically? Survodutide is the cleaner model — its two-receptor design allows attribution of observed effects to one of two pathways.
• Testing triple agonism or the specific contribution of GIP? Retatrutide is the compound to use. Its receptor potency hierarchy (GIP > GLP-1 > glucagon) and the published TRIUMPH dataset make it the best-characterized triple agonist in the research literature.
• Focused on liver fat and MASLD/MASH research? Both compounds have compelling mechanistic rationale via the glucagon receptor. Retatrutide has a larger published liver fat dataset, while survodutide’s Phase 3 MASH program generates actively accumulating data.

Key Research References

Study	Year	Type	Focus	Reference
Jastreboff et al.	2023	Phase 2 RCT	Retatrutide obesity trial	NEJM 2023
Sanyal et al.	2024	Phase 2a	Retatrutide in MASLD — 82–86% liver fat reduction	Nature Medicine 2024
Survodutide Phase 2 MASH	2023	Phase 2b RCT	Survodutide in MASH — resolution and liver fat	PMID 37565190
PMC Review — Retatrutide	2025	Review	Game-changer assessment in obesity pharmacotherapy	PMC12190491
PMC Review — Triple Agonism	2025	Review	Multi-receptor agonist comparison and mechanisms	PMC12304053
Rosenstock et al.	2023	Phase 2 RCT	Retatrutide in type 2 diabetes — HbA1c and weight	The Lancet 2023